PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain
暂无分享,去创建一个
Christer Halldin | Hiroshi Ito | L. Farde | Nathalie Ginovart | C. Halldin | V. Pike | Hiroshi Ito | N. Ginovart | L. Farde | C. Lundkvist | Victor W. Pike | Camilla Lundkvist | Julie A. McCarron | J. A. McCarron
[1] V. Pérez,et al. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. , 1994, Archives of general psychiatry.
[2] A A Lammertsma,et al. Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.
[3] J. Palacios,et al. Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors , 1987, Neuroscience.
[4] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[5] P A Sargent,et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.
[6] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[7] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] S. Stone-Elander,et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.
[9] D. Baldwin,et al. The role of serotonin in depression and anxiety , 1995, International clinical psychopharmacology.
[10] Y. Reilly,et al. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. , 1993, European journal of pharmacology.
[11] C. Dourish,et al. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.
[12] M. Minchin,et al. Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.
[13] A. S. Eison,et al. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. , 1986, The American journal of medicine.
[14] M. Hamon,et al. Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.
[15] J. Kleinman,et al. Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics , 1993, Neuropsychopharmacology.
[16] P. Grasby,et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.
[17] M. Mintun,et al. [11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. , 1994, Life sciences.
[18] S. Peroutka,et al. Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers. , 1988, Biochemical pharmacology.
[19] H. Wikström,et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 , 1997, Brain Research.
[20] P. Blier,et al. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. , 1995, Journal of clinical psychopharmacology.
[21] S. Peroutka,et al. Molecular biology of serotonin (5‐HT) receptors , 1994, Synapse.
[22] A Malizia,et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.
[23] G. Tunnicliff. Molecular basis of buspirone's anxiolytic action. , 1991, Pharmacology & toxicology.
[24] S. Paul,et al. Preclinical Pharmacology of Buspirone Hydrochloride , 1984, Pharmacotherapy.
[25] R. Schreiber,et al. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. , 1993, European journal of pharmacology.
[26] S. Hjorth,et al. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? , 1986, European journal of pharmacology.
[27] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[28] S. Hjorth,et al. The 5-HT1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[29] H. Berendsen,et al. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? , 1995, Pharmacology & therapeutics.
[30] H. Meltzer,et al. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.
[31] K Wienhard,et al. The ECAT EXACT HR: Performance of a New High Resolution Positron Scanner , 1994, Journal of computer assisted tomography.